Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-10-2017 | Editorial

The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy

Authors: C. Chiesa, K. Sjogreen Gleisner, G. Flux, J. Gear, S. Walrand, K. Bacher, U. Eberlein, E. P. Visser, N. Chouin, M. Ljungberg, M. Bardiès, M. Lassmann, L. Strigari, M. W. Konijnenberg

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2017

Excerpt

The new European Council Directive 2013/59 (http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32013L0059&from=EN), to be translated into national legislations before 6 February 2018, in article 56 (Optimisation) states: “For all medical exposure of patients for radiotherapeutic purposes, exposures of target volumes shall be individually planned and their delivery appropriately verified, taking into account that doses to non-target volumes and tissues shall be as low as reasonably achievable and consistent with the intended radiotherapeutic purpose of the exposure”. No doubt this statement holds for nuclear medicine therapy, since in article 4 of the same, directive definition 81 states that “radiotherapeutic” means pertaining to radiotherapy, including nuclear medicine for therapeutic purposes. The directive thus asks for dosimetry, as is routinely implemented in radiotherapy, using external beam or brachytherapy sources. However, in nuclear medicine therapy, absorbed dose planning is rarely performed. One of the main reasons is the amount of work needed for internal dosimetry that includes multiple whole-body counts or scintigraphy and sometimes blood samples over some days after administration. …

Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med. 1962;87:171–82.PubMed

Leeper RD. The effect of 131 I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma. J Clin Endocrinol Metab. 1973;36:1143–52.CrossRefPubMed

Lee JJ, Chung JK, Kim SE, Kang WJ, Park DJ, Lee DS, et al. Maximal safe dose of 131I after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma. Ann Nucl Med. 2008;22:727–34.CrossRefPubMed

Klubo-Gwiedzinska J, Van Nostrand D, Atkins F, Burman K, Jonklaas J, Mete M, et al. Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer. J Clin Endocrinol Metab. 2011;96:3217–25.CrossRef

Verburg FA, Hänscheid H, Biko J, Hategan MC, Lassmann M, Kreissl MC, et al. Dosimetry-guided high-activity 131I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur J Nucl Med Mol Imaging. 2010;37:896–903.CrossRefPubMed

Bianchi L, Baroli A, Lomuscio G, Pedrazzini L, Pepe A, Pozzi L, et al. Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high 131I activity: the experience of Busto Arsizio hospital (Italy). Q J Nucl Med Mol Imaging. 2012;56:515–21.PubMed

Dorn R, Kopp J, Vogt H, Heidenreich P, Carrol RG, Gulec SA. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med. 2003;44:451–6.PubMed

Hartung-Knemeyer V, Nagarajah J, Jentzen W, Ruhlmann M, Freudenberg LS, Stahl AR, et al. Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies. Ann Nucl Med. 2012;26(9):723–9.CrossRefPubMed

Verburg FA, Luster M, Giovanella L, Lassmann M, Chiesa C, Chouin N, et al. The “reset button” revisited: why high activity 131I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients. Eur J Nucl Med Mol Imaging. 2017;44(6):915–7.CrossRefPubMed

10.

Fielding SL, Flower MA, Ackery D, Kemshead JT, Lashford LS, Lewis I. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study. Eur J Nucl Med. 1991;18:308–16.CrossRefPubMed

11.

Buckley SE, Saran FH, Gaze MN, Chittenden S, Partridge M, Lancaster D, et al. Dosimetry for fractionated 131I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results. Cancer Biother Radiopharm. 2007;22(1):105–12.CrossRefPubMed

12.

Chiesa C, Mira M, Maccauro M, Spreafico C, Romito R, Morosi C, et al. Radioembolization of hepatocarcinoma with 90-Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur J Nucl Med Mol Im. 2015;42:1718–38.CrossRef

13.

Gnesin S, Canetti L, Adib S, Cherbuin N, Silva Monteiro M, Bize P, et al. Partition model-based 99mTc-MAA SPECT/CT predictive dosimetry compared with 90Y TOF PET/CT posttreatment dosimetry in radioembolization of hepatocellular carcinoma: a quantitative agreement comparison. J Nucl Med. 2016;57(11):1672–8.CrossRefPubMed

14.

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35.CrossRefPubMed

15.

Sundlöv A, Sjögreen-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, et al. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017. doi:10.1007/s00259-017-3678-4.PubMedPubMedCentral

16.

Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46:99S–106S.PubMed

17.

Kletting P, Kull T, Maaß C, Malik N, Luster M, Beer AJ, et al. Optimized peptide amount and activity for 90Y-labeled DOTATATE therapy. J Nucl Med. 2016;57:503–8.CrossRefPubMed

18.

Bergsma H, Konijnenberg MW, van der Zwan WA, Kam BL, Teunissen JJ, Kooij PP, et al. Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate. Eur J Nucl Med Mol Imaging. 2016;43(10):1802–11.CrossRefPubMedPubMedCentral

19.

Chiesa C. The individualized dosimetry in the radioembolization of hepatocarcinoma with 90Y-microspheres [abstract]. Phys Med. 2016;32 Suppl 3:169–70. 10.1016/j.ejmp.2016.07.264 CrossRef

20.

Cremonesi M, Chiesa C, Strigari L, Ferrari M, Botta F, Guerriero F, et al. Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol. 2014;4:210CrossRefPubMedPubMedCentral

21.

Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al. Yttrium90 radioembolization for intermediate-advanced hepatocarcinoma: a phase II study. Hepatology. 2013;57(5):1826–37.CrossRefPubMed

22.

Sjogreen Gleisner K. Current status and preparedness to comply to the Directive (report on European survey). Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S22 OP052.

23.

Garin E, Boucher E, Rolland Y. 99mTc-MAA-based dosimetry for liver cancer treated using 90Y-loaded microspheres: known proof of effectiveness. J Nucl Med. 2014;55:1391–2.CrossRefPubMed

24.

Tong AK, Kao YH, Too CW, Chin KF, Ng DC, Chow PK. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol. 2016;89:20150943.CrossRefPubMedPubMedCentral

25.

Willowson KP, Tapner M, The QUEST Investigator Team, Bailey DL. A multicentre comparison of quantitative 90Y PET/CT for dosimetric purposes after radioembolization with resin microspheres: the QUEST Phantom Study. Eur J Nucl Med Mol Imaging. 2015;42(8):1202–22.CrossRefPubMedPubMedCentral

26.

Smits ML, Nijsen JF, van den Bosch MA, Lam MG, Vente MA, Mali WP, et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 2012;13:1025–34.CrossRefPubMed

Title: The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy
Authors: C. Chiesa
K. Sjogreen Gleisner
G. Flux
J. Gear
S. Walrand
K. Bacher
U. Eberlein
E. P. Visser
N. Chouin
M. Ljungberg
M. Bardiès
M. Lassmann
L. Strigari
M. W. Konijnenberg
Publication date: 01-10-2017
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-017-3707-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2017

Relation between thoracic aortic inflammation and features of plaque vulnerability in the coronary tree in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. An FDG-positron emission tomography and optical coherence tomography study

The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer

Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of 18F-FDG PET

Hybrid 18F–FDG PET/MRI might improve locoregional staging of breast cancer patients prior to neoadjuvant chemotherapy

The ninth international congress of the Croatian Society of Nuclear Medicine – Rovinj, May 04–07, 2017

Influence of body mass index and type of low-level exercise on the side effect profile of regadenoson